Your browser doesn't support javascript.
loading
Myricetin: targeting signaling networks in cancer and its implication in chemotherapy.
Javed, Zeeshan; Khan, Khushbukhat; Herrera-Bravo, Jesús; Naeem, Sajid; Iqbal, Muhammad Javed; Raza, Qamar; Sadia, Haleema; Raza, Shahid; Bhinder, Munir; Calina, Daniela; Sharifi-Rad, Javad; Cho, William C.
Afiliación
  • Javed Z; Office of Research Innovation and Commercialization, Lahore Garrison University, Lahore, Pakistan.
  • Khan K; Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Sector H-12, Islamabad, 44000, Pakistan.
  • Herrera-Bravo J; Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Santiago, Chile.
  • Naeem S; Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, 4811230, Temuco, Chile.
  • Iqbal MJ; Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, Lanzhou, 730000, China.
  • Raza Q; Department of Biotechnology, Faculty of Sciences, University of Sialkot, Sialkot, Pakistan. javed.iqbal@uskt.edu.pk.
  • Sadia H; Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, Punjab, Pakistan.
  • Raza S; Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences, Quetta, 87100, Pakistan.
  • Bhinder M; Office of Research Innovation and Commercialization, Lahore Garrison University, Lahore, Pakistan.
  • Calina D; Department of Human Genetics & Molecular Biology, University of Health Sciences, Lahore, 54600, Pakistan.
  • Sharifi-Rad J; Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania. calinadaniela@gmail.com.
  • Cho WC; Facultad de Medicina, Universidad del Azuay, Cuenca, Ecuador. javad.sharifirad@gmail.com.
Cancer Cell Int ; 22(1): 239, 2022 Jul 28.
Article en En | MEDLINE | ID: mdl-35902860
ABSTRACT
The gaps between the complex nature of cancer and therapeutics have been narrowed down due to extensive research in molecular oncology. Despite gathering massive insight into the mysteries of tumor heterogeneity and the molecular framework of tumor cells, therapy resistance and adverse side effects of current therapeutic remain the major challenge. This has shifted the attention towards therapeutics with less toxicity and high efficacy. Myricetin a natural flavonoid has been under the spotlight for its anti-cancer, anti-oxidant, and anti-inflammatory properties. The cutting-edge molecular techniques have shed light on the interplay between myricetin and dysregulated signaling cascades in cancer progression, invasion, and metastasis. However, there are limited data available regarding the nano-delivery platforms composed of myricetin in cancer. In this review, we have provided a comprehensive detail of myricetin-mediated regulation of different cellular pathways, its implications in cancer prevention, preclinical and clinical trials, and its current available nano-formulations for the treatment of various cancers.
Palabras clave